SHC Stock Analysis: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$19.57
0.35 (1.82%)
▲
5d:
+3.6%
30d:
+11.89%
90d:
+24.57%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SHC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SHC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.25
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$15.06
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $19.57, which is considered extended relative to its 30-day fair value range of $17.57 to $18.91. The stock's valuation (Forward PE: 17.5) is in line with its historical norms (16.4). At these levels, the market is pricing in 2.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $19.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.72 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $19.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.72 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.57 -
$18.91
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.9%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.9% below Wall St target ($22.72)
- NEUTRAL: Market pricing in 2.2% annual earnings growth - fairly valued
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.57 -
$18.91
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.39
Resistance Level
$19.63
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.49
Wall Street Target
$22.72
(+20.9%)
Revenue Growth (YoY)
9.2%
Earnings Growth (YoY)
569.5%
Profit Margin
13.4%
Valuation Premium vs History
+2.2% premium
PE vs Historical
17.5 vs 16.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.2%
(market-implied from PE analysis)
1-Year Target
$19.21
(+2%)
2-Year Target
$19.64
(+4%)
3-Year Target
$20.07
(+7%)
3-Yr Target (if PE normalizes)
(PE: 17→16)
PE COMPRESSION
$18.82
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 9.2%)
$28.13
(+50%)
Base:
(SPY PE: 17.5, Growth: 9.2%)
$24.46
(+30%)
Bear:
(PE: 14.9, Growth: 9.2%)
$20.79
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 33.14 | Current EPS (TTM): $0.57
Bull Case
$39.18
(+100%)
Analyst growth 88.6%, PE expands to 36.5
Base Case
$35.62
(+82%)
Market implied 88.6%, PE stable at 33.1
Bear Case
$12.85
(-34%)
Severe decline -20.0%, PE contracts to 28.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 7:13 AM ET
Data refreshes hourly during market hours. Next update: 8:13 AM
Data refreshes hourly during market hours. Next update: 8:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gtcr Investment Xi Llc
SELL
10000000 shares
2026-03-06
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$631 | 41 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 50 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 43 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$331 | 38 SELL |
